Immunome IMNM Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunome's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunome's operating lease liabilities (total)?
- Immunome (IMNM) reported operating lease liabilities (total) of $3.69M in Q1 2026.
- How has Immunome's operating lease liabilities (total) changed year-over-year?
- Immunome's operating lease liabilities (total) decreased by 22.6% year-over-year, from $4.77M to $3.69M.
- What is the long-term trend for Immunome's operating lease liabilities (total)?
- Over 2 years (2021 to 2025), Immunome's operating lease liabilities (total) has grown at a 177.7% compound annual growth rate (CAGR), from $500K to $3.86M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.